More Starpharma Holdings Limited news
Starpharma Holdings LimitedASX: SPL

SPL Commences pivotal phase 3 VivaGel BV treatment trials

Mar 30, 2016 at 5:31 AM EDT · Issued by Starpharma Holdings Limited

Filed with ASX · Mar 30, 2016 at 5:31 AM EDT

On 6ix: 6ix.com/news/spl-commences-pivotal-phase-3-vivagel-bv-treatment-trials

View Attachment

6ix hasn’t read this filing yet.

Starpharma Holdings Limited on 6ix

Earlier from Starpharma

  • Starpharma to recoup $6 million cash for overseas R&DMar 30, 2016
  • Starpharma signs cancer drug agreement with AstraZenecaMar 30, 2016
  • Starpharma presenting at Bell Potter LifeScience ConferenceMar 30, 2016
  • SPL docetaxel superior to Taxotere across multiple cancersMar 30, 2016
  • Dendrimers improve anticancer efficacy lung metastasis modelMar 30, 2016

Later from Starpharma

  • Advances leading cancer therapeutic in drug delivery programMar 30, 2016
  • GSK awarded funds for dermal treatment with SPL`s dendrimersMar 30, 2016
  • SPL Commences VivaGel Bacterial Vaginosis Prevention StudyMar 30, 2016
  • SPL: Terminates Reckitt agreement and signs with AnsellMar 30, 2016
  • Starpharma secures European (EMA) agreement on BV Phase 3Mar 30, 2016
All Starpharma news releases↗

Follow Starpharma into a list and get an email when it puts out news.

Follow Starpharma
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer